Diagnostic efficacy of free prostate-specific antigen/total prostate-specific antigen ratio for the diagnosis of prostate cancer in low concentration (≤4 ng/ml) and intermediate levels of total prostate-specific antigen (4.01-10.0 ng/ml)
Accessinfo:eu-repo/semantics/openAccessAttribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0)https://creativecommons.org/licenses/by-nc-sa/3.0/
MetadataShow full item record
CitationÇalışkan, S. (2017). Diagnostic efficacy of free prostate-specific antigen/total prostate-specific antigen ratio for the diagnosis of prostate cancer in low concentration (≤4 ng/ml) and intermediate levels of total prostate-specific antigen (4.01–10.0 ng/ml). Journal of Cancer Research and Therapeutics, 13(2), 279-283.
Aim of Study: Serum prostate-specific antigen (PSA) is a useful tumor biomarker for prostate cancer (PCa) diagnosis. In this study, I aimed to compare the free/total PSA (fPSA%) with PSA alone for their usefulness in diagnosis for PCa. Methods: The patients who underwent prostate biopsy between January 2010 and January 2015 were evaluated retrospectively. Data were expressed as a mean + standard error and P < 0.05 as considered with statistical significance (Med Calc 14.12-2014). The receiver operating characteristic curves were calculated to study the sensitivity and specificity of fPSA and PSA and compared to each other in different PSA levels. Results: There were 1055 patients in the study. The mean age of the patients was 64.2 + 7.5 and 66.3 + 6.4 years in Groups 1 and 2. The mean PSA and free/total PSA of the patients was 2.79 + 1 ng/ml, 0.2 + 0.08 and 6.49 + 1.59 ng/ml and 0.19 + 0.09 in Groups 1 and 2, respectively. I found the optimal cutoff for fPSA% was ?18 and ?14 in Groups 1 and 2 with a sensitivity of 62-45% and specificity of 58-79%. There was a statistical significant difference for fPSA when comparing the area under curve in the PSA level of 4.01-10 ng/ml (P = 0.0009). Conclusion: In this study, serum fPSA% has advantages for diagnosis of PCa when comparing PSA alone in different levels of PSA. These advantages are significant in PSA level of 4.01-10 ng/ml. © 2017 Indian Journal of Ophthalmology | Published by Wolters Kluwer - Medknow.
SourceJournal of Cancer Research and Therapeutics
Showing items related by title, author, creator and subject.
Prevelance of prostate cancer among Turkish men with prostate-specific antigen level of ≤100 ng/ml Çalışkan, Selahattin (Wolters Kluwer Medknow Publications, 2018)Aim of Study: Prostate cancer (PCa) is one of the most common cancers among men and has become a significant health problem in developing and developed countries. Prostate-specific antigen (PSA) is a useful marker for ...
Awareness of prostate cancer diagnosis and management among Turkish males: a cross sectional study from Çorum Introduction: Prostate cancer is the most common malignancy among men in the United States and the second most common cancer in Turkey. The incidence of prostate cancer is increasing in industrialized countries. Aim: The ...
Impact of prostate specific antigen level on oncological outcomes after open radical prostatectomy Objective: To compare the impact of prostate specific antigen (PSA) on oncological outcomes in the patients with 4-10 and 10.01-20 ng/ml PSA level. Study Design: Retrospective comparative study. Place and Duration of Study: ...